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Introduction
Varicella infection is a highly contagious disease which can
have a complicated course especially in immunocompro-
mised children and children receiving immunomodulatory
therapy.
Objectives
to evaluate safety and efficacy of varicella vaccination in
children with JIA treated also with biologic therapy.
Methods
We designed a prospective study on a long term follow up.
Five patients with JIA (median age 5, range 3,5-7 years),
treated also with biologic therapy (2 etanercept,
2 tocilizumab, 1 infliksimab), received 2 doses of varicella
vaccine. One patient treated with etanercept received the
first dose before starting etanercept, others received both
doses on biologic therapy. Before vaccination JIA was
stable on therapy and lymphocytic populations (CD3,
CD4, CD8, CD19, NK) were normal in all vaccinated
children. All had negative varicella serology. Parents were
asked for written informed consent before vaccination.
After vaccination children were followed for disease
activity, infections and protective antibodies (pAb) against
varicella virus on a long term.
Results
There were no serious side effects after vaccination and no
clinical varicella infection in a period of 3 months after
vaccination. One patient had mild local reaction after the
first dose. One patient treated with etanercept got adeno-
virus infection 3 days after the second dose of vaccine.
Disease activity remained stable in all patients in a period
of three months after the second dose. Four patients (75%)
had pAb against varicella virus 6 weeks after the second
dose. One patient treated with infliximab and methotrex-
ate didn’t develop pAb after the second dose. Two patients
treated with etanercept developed low levels of pAb after
the second dose. Two patients treated with tocilizumab
developed low levels of pAb even after the first dose and
very high levels of pAb after the second dose. One patient
treated with etanercept got varicella infection 4 months
after the second dose despite the protective, however, low
levels of pAb. Varicella infection was mild. The other
patient treated with etanercept lost his pAb 22 months
after the second dose. One patient treated with tocilizu-
mab still has low pAb 27 months after the second dose
and one patient treated with tocilizumab has very high
pAb 3 month after the second dose.
Conclusion
Varicella vaccination appears to be safe in JIA patients
treated also with biologic therapy. However, it is possi-
ble that protection is only short term and does not
always protect against infection. Follow up of pAb is
recommended and the need for revaccination should
probably be carefully considered in cases with high risk
of varicella infection. Larger cohort studies are needed
to obtain more reliable data on varicella vaccination in
JIA patient treated with biologic therapy.
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